The US Patent and Trademark Office (USPTO) has proposed a new terminal disclaimer practice, which has been welcomed by the Federal Trade Commission (FTC). This proposal aims to expand settlement disclosure requirements. Additionally, there are discussions about US product hopping legislation potentially offering $3 billion in savings. A drug patent and exclusivity study report has been published by the USPTO.